Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is a life threatening global health problem with only two drugs available for treatment (benznidazole and nifurtimox), both having variable efficacy in the chronic stage of the disease and high rates of adverse drug react...
Saved in:
Main Authors: | Jennifer Riley (Author), Stephen Brand (Author), Michael Voice (Author), Ivan Caballero (Author), David Calvo (Author), Kevin D Read (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2015-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51.
by: Shamila S Gunatilleke, et al.
Published: (2012) -
Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.
by: Chiung-Kuang Chen, et al.
Published: (2010) -
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
by: Lorna M MacLean, et al.
Published: (2018) -
Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
by: Chiung-Kuang Chen, et al.
Published: (2009) -
Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
by: Frédéric-Antoine Dauchy, et al.
Published: (2016)